Beyond loss of frataxin: The complex molecular pathology of friedreich ataxia

Discovery Medicine

Volumn 17, Issue 91, 2014, Pages 25-36

  Evans Galea, Marguerite V ^a   Lockhart, Paul J ^a   Galea, Charles A ^b   Hannan, Anthony J ^c   Delatycki, Martin ^a  

^a MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FRATAXIN; OCTAMER TRANSCRIPTION FACTOR 4; SERUM RESPONSE FACTOR;

5' UNTRANSLATED REGION; ARTICLE; CPG ISLAND; DISEASE COURSE; DISEASE SEVERITY; DNA METHYLATION; EPIGENETICS; FRIEDREICH ATAXIA; GENE SILENCING; HISTONE ACETYLATION; HUMAN; LIPID PEROXIDATION; MOLECULAR PATHOLOGY; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN STABILITY; QUALITY OF LIFE; TRANSCRIPTION INITIATION SITE;

ALLELES; FRIEDREICH ATAXIA; HUMANS; IRON-BINDING PROTEINS; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84892718090     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (99)

1. Al-Mahdawi S, Pinto RM, Ismail O, Varshney D, Lymperi S, Sandi C, Trabzuni D, Pook M. The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues. Hum Mol Genet 17(5):735-746, 2008.
2. Al-Mahdawi S, Pinto RM, Ruddle P, Carroll C, Webster Z, Pook M. GAA repeat instability in Friedreich ataxia YAC transgenic mice. Genomics 84(2):301-310, 2004.
3. Al-Mahdawi S, Pinto RM, Varshney D, Lawrence L, Lowrie MB, Hughes S, Webster Z, Blake J, Cooper JM, King R, Pook MA. GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology. Genomics 88(5):580-590, 2006.
4. Ambros V. microRNAs: tiny regulators with great potential. Cell 107(7):823-826, 2001.
5. Arnott S, Dover SD, Elliott A. Structure of beta-poly-L-alanine: refined atomic co-ordinates for an anti-parallel beta-pleated sheet. J Mol Biol 30(1):201-208, 1967.
6. Babcock M, De Silva D, Oaks R, Davis-Kaplan S, Jiralerspong S, Montermini L, Pandolfo M, Kaplan J. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science 276(5319):1709-1712, 1997.
7. Bencze KZ, Yoon T, Millan-Pacheco C, Bradley PB, Pastor N, Cowan JA, Stemmler TL. Human frataxin: iron and ferrochelatase binding surface. Chem Commun (Camb) (18):1798-1800, 2007.
8. Bidichandani SI, Ashizawa T, Patel PI. The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure. Am J Hum Genet 62(1):111-121, 1998.
9. Bird A. Perceptions of epigenetics. Nature 447(7143):396-398, 2007.
10. Bit-Avragim N, Perrot A, Schols L, Hardt C, Kreuz FR, Zuhlke C, Bubel S, Laccone F, Vogel HP, Dietz R, Osterziel KJ. The GAA repeat expansion in intron 1 of the frataxin gene is related to the severity of cardiac manifestation in patients with Friedreich's ataxia. J Mol Med 78(11):626-632, 2001.
11. Bridwell-Rabb J, Winn AM, Barondeau DP. Structure-function analysis of Friedreich's ataxia mutants reveals determinants of frataxin binding and activation of the Fe-S assembly complex. Biochemistry 50(33):7265-7274, 2011.
12. Bulteau AL, O'neill HA, Kennedy MC, Ikeda-Saito M, Isaya G, Szweda LI. Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity. Science 305(5681):242-245, 2004.
13. Campuzano V, Montermini L, Lutz Y, Cova L, Hindelang C, Jiralerspong S, Trottier Y, Kish S, Faucheux B, Trouillas P, Authier F, Durr A, Mandel J, Vescovi A, Pandolfo M, Koenig M. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet 6(11):1771-1780, 1997.
14. Campuzano V, Montermini L, Molto M, Pianese L, Cossee M, Cavalcanti F, Monros E, Rodius F, Duclos F, Monticelli A, Zara F, Canizares J, Koutnikova H, Bidichandani S, Gellera C, Brice A, Trouillas P, De Michele G, Filla A, De Frutos R, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271:1423-1427, 1996.
15. Castaldo I, Pinelli M, Monticelli A, Acquaviva F, Giacchetti M, Filla A, Sacchetti S, Keller S, Avvedimento VE, Chiariotti L, Cocozza S. DNA methylation in intron 1 of the frataxin gene is related to GAA repeat length and age of onset in Friedreich ataxia patients. J Med Genet 45(12):808-812, 2008.
16. Clark RM, De Biase I, Malykhina AP, Al-Mahdawi S, Pook M, Bidichandani SI. The GAA triplet-repeat is unstable in the context of the human FXN locus and displays age-dependent expansions in cerebellum and DRG in a transgenic mouse model. Hum Genet 120(5):633-640, 2007.
17. Cnop M, Igoillo-Esteve M, Rai M, Begu A, Serroukh Y, Depondt C, Musuaya AE, Marhfour I, Ladriere L, Moles Lopez X, Lefkaditis D, Moore F, Brion JP, Cooper JM, Schapira AH, Clark A, Koeppen AH, Marchetti P, Pandolfo M, Eizirik DL, et al. Central role and mechanisms of beta-cell dysfunction and death in friedreich ataxia-associated diabetes. Ann Neurol 72(6):971-982, 2012.
18. Connelly T, Farmer JM, Lynch DR, Doty RL. Olfactory dysfunction in degenerative ataxias. J Neurol Neurosurg Psych 74(10):1435-1437, 2003.
19. Corben L, Delatycki M, Bradshaw J, Horne M, Fahey M, Churchyard A, Georgiou-Karistianis N. Impairment in motor reprogramming in Friedreich ataxia reflecting possible cerebellar dysfunction. J Neurol 257(5):782-791, 2010.
20. Cossee M, Durr A, Schmitt M, Dahl N, Trouillas P, Allinson P, Kostrzewa M, Nivelon-Chevallier A, Gustavson KH, Kohlschutter A, Muller U, Mandel JL, Brice A, Koenig M, Cavalcanti F, Tammaro A, De Michele G, Filla A, Cocozza S, Labuda M, et al. Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol 45(2):200-206, 1999.
21. Cossee M, Puccio H, Gansmuller A, Koutnikova H, Dierich A, Lemeur M, Fischbeck K, Dolle P, Koenig M. Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum Mol Genet 9(8):1219-1226, 2000.
22. Cossee M, Schmitt M, Campuzano V, Reutenauer L, Moutou C, Mandel JL, Koenig M. Evolution of the Friedreich's ataxia trinucleotide repeat expansion: founder effect and premutations. Proc Natl Acad Sci U S A 94(14):7452-7457, 1997.
23. Daughters RS, Tuttle DL, Gao W, Ikeda Y, Moseley ML, Ebner TJ, Swanson MS, Ranum LP. RNA gain-of-function in spinocerebellar ataxia type 8. PLoS Genet 5(8):e1000600, 2009.
24. De Biase I, Chutake YK, Rindler PM, Bidichandani SI. Epigenetic silencing in Friedreich ataxia is associated with depletion of CTCF (CCCTC-binding factor) and antisense transcription. PLoS One 4(11):e7914, 2009.
25. De Biase I, Rasmussen A, Endres D, Al-Mahdawi S, Monticelli A, Cocozza S, Pook M, Bidichandani SI. Progressive GAA expansions in dorsal root ganglia of Friedreich's ataxia patients. Ann Neurol 61(1):55-60, 2007a.
26. De Biase I, Rasmussen A, Monticelli A, Al-Mahdawi S, Pook M, Cocozza S, Bidichandani SI. Somatic instability of the expanded GAA triplet-repeat sequence in Friedreich ataxia progresses throughout life. Genomics 90(1):1-5, 2007b.
27. Delatycki M, Paris D, Gardner R, Forshaw K, Nicholson G, Nassif N, Williamson R, Forrest S. Sperm DNA analysis in a Friedreich ataxia premutation carrier suggests both meiotic and mitotic expansion in the FRDA gene. J Med Genet 35(9):713-716, 1998.
28. Delatycki MB, Williamson R, Forrest SM. Friedreich ataxia: an overview. J Med Genet 37(1):1-8, 2000.
29. Deutsch EC, Santani AB, Perlman SL, Farmer JM, Stolle CA, Marusich MF, Lynch DR. A rapid, noninvasive immunoassay for frataxin: Utility in assessment of Friedreich ataxia. Mol Genet Metab 101(2-3):238-245, 2010.
30. Dhe-Paganon S, Shigeta R, Chi YI, Ristow M, Shoelson SE. Crystal structure of human frataxin. J Biol Chem 275(40):30753-30756, 2000.
31. Evans-Galea MV, Carrodus N, Rowley SM, Corben LA, Tai G, Saffery R, Galati JC, Wong NC, Craig JM, Lynch DR, Regner SR, Brocht AF, Perlman SL, Bushara KO, Gomez CM, Wilmot GR, Li L, Varley E, Delatycki MB, Sarsero JP. FXN methylation predicts expression and clinical outcome in Friedreich ataxia. Ann Neurol 71(4):487-497, 2012.
32. Fahey MC, Cremer PD, Aw ST, Millist L, Todd MJ, White OB, Halmagyi M, Corben LA, Collins V, Churchyard AJ, Tan K, Kowal L, Delatycki MB. Vestibular, saccadic and fixation abnormalities in genetically confirmed Friedreich ataxia. Brain 131:1035-1045, 2008.
33. Fielding J, Corben L, Cremer P, Millist L, White O, Delatycki M. Disruption to higher order processes in Friedreich ataxia. Neuropsychologia 48(1):235-242, 2010.
34. Filla A, De Michele G, Cavalcanti F, Pianese L, Monticelli A, Campanella G, Cocozza S. The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am J Hum Genet 59(3):554-560, 1996.
35. Gendron TF, Cosio DM, Petrucelli L. c9RAN translation: a potential therapeutic target for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia. Expert Opin Ther Targets 17(9):991-995, 2013.
36. Gibson TJ, Koonin EV, Musco G, Pastore A, Bork P. Friedreich's ataxia protein: phylogenetic evidence for mitochondrial dysfunction. Trends Neurosci 19(11):465-468, 1996.
37. Gonzalez-Cabo P, Vazquez-Manrique RP, Garcia-Gimeno MA, Sanz P, Palau F. Frataxin interacts functionally with mitochondrial electron transport chain proteins. Hum Mol Genet 14(15):2091-2098, 2005.
38. Grabczyk E, Mancuso M, Sammarco MC. A persistent RNA.DNA hybrid formed by transcription of the Friedreich ataxia triplet repeat in live bacteria, and by T7 RNAP in vitro. Nucleic Acids Res 35(16):5351-5359, 2007.
39. Grabczyk E, Usdin K. The GAA*TTC triplet repeat expanded in Friedreich's ataxia impedes transcription elongation by T7 RNA polymerase in a length and supercoil dependent manner. Nucleic Acids Res 28(14):2815-2822, 2000.
40. Greene E, Entezam A, Kumari D, Usdin K. Ancient repeated DNA elements and the regulation of the human frataxin promoter. Genomics 85(2):221-230, 2005.
41. Greene E, Mahishi L, Entezam A, Kumari D, Usdin K. Repeat-induced epigenetic changes in intron 1 of the frataxin gene and its consequences in Friedreich ataxia. Nucleic Acids Res 35(10):3383-3390, 2007.
42. Hagerman PJ, Hagerman RJ. The fragile-X premutation: a maturing perspective. Am J Hum Genet 74(5):805-816, 2004.
43. Harding AE. Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 104(3):589-620, 1981.
44. He Y, Alam SL, Proteasa SV, Zhang Y, Lesuisse E, Dancis A, Stemmler TL. Yeast frataxin solution structure, iron binding, and ferrochelatase interaction. Biochemistry 43(51):16254-16262, 2004.
45. Herman D, Jenssen K, Burnett R, Soragni E, Perlman SL, Gottesfeld JM. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol 2(10):551-558, 2006.
46. Jiralerspong S, Liu Y, Montermini L, Stifani S, Pandolfo M. Frataxin shows developmentally regulated tissue-specific expression in the mouse embryo. Neurobiol Dis 4(2):103-113, 1997.
47. Johnson JM, Castle J, Garrett-Engele P, Kan Z, Loerch PM, Armour CD, Santos R, Schadt EE, Stoughton R, Shoemaker DD. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 302(5653):2141-2144, 2003.
48. Kelly M, Bagnall RD, Peverill RE, Donelan L, Corben L, Delatycki MB, Semsarian C. A polymorphic miR-155 binding site in AGTR1 is associated with cardiac hypertrophy in Friedreich ataxia. J Mol Cell Cardiol 51(5):848-854, 2011.
49. Kim E, Napierala M, Dent SY. Hyperexpansion of GAA repeats affects post-initiation steps of FXN transcription in Friedreich's ataxia. Nucleic Acids Res 39(19):8366-8377, 2011.
50. Koeppen AH, Kuntzsch EC, Bjork ST, Ramirez RL, Mazurkiewicz JE, Feustel PJ. Friedreich ataxia: metal dysmetabolism in dorsal root ganglia. Acta Neuropathol Comm 1(1):26, 2013.
51. Koeppen AH, Mazurkiewicz JE. Friedreich ataxia: neuropathology revised. J Neuropathol Exp Neurol 72(2):78-90, 2013.
52. Koeppen AH, Morral JA, Davis AN, Qian J, Petrocine SV, Knutson MD, Gibson WM, Cusack MJ, Li D. The dorsal root ganglion in Friedreich's ataxia. Acta Neuropathol 118(6):763-776, 2009.
53. Ku S, Soragni E, Campau E, Thomas EA, Altun G, Laurent LC, Loring JF, Napierala M, Gottesfeld JM. Friedreich's ataxia induced pluripotent stem cells model intergenerational GAATTC triplet repeat instability. Cell Stem Cell 7(5):631-637, 2010.
54. Kumari D, Biacsi RE, Usdin K. Repeat expansion affects both transcription initiation and elongation in friedreich ataxia cells. J Biol Chem 286(6):4209-4215, 2011.
55. Lamont P, Davis M, Wood N. Identification and sizing of the GAA trinucleotide repeat expansion of Friedreich's ataxia in 56 patients. Clinical and genetic correlates. Brain 120(4):673-680, 1997.
56. Lesuisse E, Santos R, Matzanke BF, Knight SA, Camadro JM, Dancis A. Iron use for haeme synthesis is under control of the yeast frataxin homologue (Yfh1). Hum Mol Genet 12(8):879-889, 2003.
57. Li K, Singh A, Crooks DR, Dai X, Cong Z, Pan L, Ha D, Rouault TA. Expression of human frataxin is regulated by transcription factors SRF and TFAP2. PLoS One 5(8):e12286, 2010.
58. Lotz B. Crystal structure of polyglycine I. J Mol Biol 87(2):169-180, 1974.
59. Lynch DR, Farmer JM, Balcer LJ, Wilson RB. Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy.[see comment]. Arch Neurol 59(5):743-747, 2002.
60. Mahishi LH, Hart RP, Lynch DR, Ratan RR. miR-886-3p levels are elevated in Friedreich ataxia. J Neurosci 32(27):9369-9373, 2012.
61. Miranda CJ, Santos MM, Ohshima K, Smith J, Li L, Bunting M, Cossee M, Koenig M, Sequeiros J, Kaplan J, Pandolfo M. Frataxin knockin mouse. FEBS Lett 512(1-3):291-297, 2002.
62. Monros E, Molto MD, Martinez F, Canizares J, Blanca J, Vilchez JJ, Prieto F, De Frutos R, Palau F. Phenotype correlation and intergenerational dynamics of the Friedreich ataxia GAA trinucleotide repeat. Am J Hum Genet 61(1):101-110, 1997.
63. Montermini L, Kish SJ, Jiralerspong S, Lamarche JB, Pandolfo M. Somatic mosaicism for Friedreich's ataxia GAA triplet repeat expansions in the central nervous system. Neurology 49(2):606-610, 1997.
64. Ohshima K, Montermini L, Wells RD, Pandolfo M. Inhibitory effects of expanded GAA.TTC triplet repeats from intron I of the Friedreich ataxia gene on transcription and replication in vivo. J Biol Chem 273(23):14588-14595, 1998.
65. Oktay Y, Dioum E, Matsuzaki S, Ding K, Yan LJ, Haller RG, Szweda LI, Garcia JA. Hypoxia-inducible factor 2alpha regulates expression of the mitochondrial aconitase chaperone protein frataxin. J Biol Chem 282(16):11750-11756, 2007.
66. Packer AN, Xing Y, Harper SQ, Jones L, Davidson BL. The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease. J Neurosci 28(53):14341-14346, 2008.
67. Pandolfo M. Friedreich's ataxia. In: Genetic Instabilities and Neurological Diseases. RD Wells, T Ashizawa (Eds.) )pp 277-296. Academic Press, USA, 2006.
68. Pearson CE. Repeat associated non-ATG translation initiation: one DNA, two transcripts, seven reading frames, potentially nine toxic entities! PLoS Genet 7(3):e1002018, 2011.
69. Perlman SL. A review of Friedreich ataxia clinical trial results. J Child Neurol 27(9):1217-1222, 2012.
70. Pianese L, Turano M, Lo Casale MS, De Biase I, Giacchetti M, Monticelli A, Criscuolo C, Filla A, Cocozza S. Real time PCR quantification of frataxin mRNA in the peripheral blood leucocytes of Friedreich ataxia patients and carriers. J Neurol Neurosurg Psychiatry 75(7):1061-1063, 2004.
71. Porter N, Downes SM, Fratter C, Anslow P, Nemeth AH. Catastrophic visual loss in a patient with Friedreich ataxia. Arch Ophthalmol 125(2):273-274, 2007.
72. Puccio H. Conditional mouse models for Friedreich ataxia, a neurodegenerative disorder associating cardiomyopathy. Handb Exp Pharmacol (178):365-375, 2007.
73. Puccio H, Simon D, Cossee M, Criqui-Filipe P, Tiziano F, Melki J, Hindelang C, Matyas R, Rustin P, Koenig M. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet 27(2):181-186, 2001.
74. Puspasari N, Rowley SM, Gordon L, Lockhart PJ, Ioannou PA, Delatycki MB, Sarsero JP. Long range regulation of human FXN gene expression. PLoS One 6(7):e22001, 2011.
75. Rai M, Soragni E, Chou CJ, Barnes G, Jones S, Rusche JR, Gottesfeld JM, Pandolfo M. Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model. PLoS One 5(1):e8825, 2010.
76. Rai M, Soragni E, Jenssen K, Burnett R, Herman D, Coppola G, Geschwind DH, Gottesfeld JM, Pandolfo M. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS One 3(4):e1958, 2008.
77. Rance G, Corben L, Barker E, Carew P, Chisari D, Rogers M, Dowell R, Jamaluddin S, Bryson R, Delatycki MB. Auditory perception in individuals with Friedreich's ataxia. Audiol Neurootol 15(4):229-240, 2010.
78. Ranum LP, Cooper TA. RNA-mediated neuromuscular disorders. Annu Rev Neurosci 29:259-277, 2006.
79. Roman EA, Faraj SE, Gallo M, Salvay AG, Ferreiro DU, Santos J. Protein stability and dynamics modulation: the case of human frataxin. PLoS One 7(9):e45743, 2012.
80. Rouault TA, Tong WH. Iron-sulfur cluster biogenesis and human disease. Trends Genet 24(8):398-407, 2008.
81. Sakamoto N, Chastain PD, Parniewski P, Ohshima K, Pandolfo M, Griffith JD, Wells RD. Sticky DNA: self-association properties of long GAA TTC repeats in RRY triplex structures from Friedreich's ataxia. Mol Cell 3(4):465-475, 1999.
82. Santoro L, De Michele G, Perretti A, Crisci C, Cocozza S, Cavalcanti F, Ragno M, Monticelli A, Filla A, Caruso G. Relation between trinucleotide GAA repeat length and sensory neuropathy in Friedreich's ataxia. J Neurol Neurosurg Psychiatry 66(1):93-96, 1999.
83. Santos R, Lefevre S, Sliwa D, Seguin A, Camadro JM, Lesuisse E. Friedreich ataxia: molecular mechanisms, redox considerations, and therapeutic opportunities. Antioxid Redox Signal 13(5):651-690, 2010.
84. Sarsero JP, Holloway TP, Li L, Mclenachan S, Fowler KJ, Bertoncello I, Voullaire L, Gazeas S, Ioannou PA. Evaluation of an FRDA-EGFP genomic reporter assay in transgenic mice. Mamm Genome 16(4):228-241, 2005.
85. Saveliev A, Everett C, Sharpe T, Webster Z, Festenstein R. DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing. Nature 422(6934):909-913, 2003.
86. Schagerlof U, Elmlund H, Gakh O, Nordlund G, Hebert H, Lindahl M, Isaya G, Al-Karadaghi S. Structural basis of the iron storage function of frataxin from single-particle reconstruction of the iron-loaded oligomer. Biochemistry 47(17):4948-4954, 2008.
87. Schmucker S, Argentini M, Carelle-Calmels N, Martelli A, Puccio H. The in vivo mitochondrial two-step maturation of human frataxin. Hum Mol Genet 17(22):3521-3531, 2008.
88. Schoenfeld RA, Napoli E, Wong A, Zhan S, Reutenauer L, Morin D, Buckpitt AR, Taroni F, Lonnerdal B, Ristow M, Puccio H, Cortopassi GA. Frataxin deficiency alters heme pathway transcripts and decreases mitochondrial heme metabolites in mammalian cells. Hum Mol Genet 14(24):3787-3799, 2005.
89. Soragni E, Herman D, Dent SY, Gottesfeld JM, Wells RD, Napierala M. Long intronic GAA*TTC repeats induce epigenetic changes and reporter gene silencing in a molecular model of Friedreich ataxia. Nucleic Acids Res 36(19):6056-6065, 2008.
90. Stemmler TL, Lesuisse E, Pain D, Dancis A. Frataxin and mitochondrial FeS cluster biogenesis. J Biol Chem 285(35):26737-26743, 2010.
91. Straussman R, Nejman D, Roberts D, Steinfeld I, Blum B, Benvenisty N, Simon I, Yakhini Z, Cedar H. Developmental programming of CpG island methylation profiles in the human genome. Nat Struct Mol Biol 16(5):564-571, 2009.
92. Talbert PB, Henikoff S. Spreading of silent chromatin: inaction at a distance. Nat Rev Genet 7(10):793-803, 2006.
93. Todd PK, Oh SY, Krans A, He F, Sellier C, Frazer M, Renoux AJ, Chen KC, Scaglione KM, Basrur V, Elenitoba-Johnson K, Vonsattel JP, Louis ED, Sutton MA, Taylor JP, Mills RE, Charlet-Berguerand N, Paulson HL. CGG repeat-associated translation mediates neurodegeneration in fragile X tremor ataxia syndrome. Neuron 78(3):440-455, 2013.
94. Tsou AY, Paulsen EK, Lagedrost SJ, Perlman SL, Mathews KD, Wilmot GR, Ravina B, Koeppen AH, Lynch DR. Mortality in Friedreich ataxia. J Neurol Sci 307(1-2):46-49, 2011.
95. Wells RD. DNA triplexes and Friedreich ataxia. FASEB J 22(6):1625-1634, 2008.
96. Willis JH, Isaya G, Gakh O, Capaldi RA, Marusich MF. Lateral-flow immunoassay for the frataxin protein in Friedreich's ataxia patients and carriers. Mol Genet Metab 94(4):491-497, 2008.
97. Wilson CL, Fahey MC, Corben LA, Collins VR, Churchyard AJ, Lamont PJ, Delatycki MB. Quality of life in Friedreich ataxia: what clinical, social and demographic factors are important? Eur J Neurol 14(9):1040-1047, 2007.
98. Xia H, Cao Y, Dai X, Marelja Z, Zhou D, Mo R, Al-Mahdawi S, Pook MA, Leimkuhler S, Rouault TA, Li K. Novel frataxin isoforms may contribute to the pathological mechanism of friedreich ataxia. PLoS One 7(10):e47847, 2012.
99. Zu T, Gibbens B, Doty NS, Gomes-Pereira M, Huguet A, Stone MD, Margolis J, Peterson M, Markowski TW, Ingram MA, Nan Z, Forster C, Low WC, Schoser B, Somia NV, Clark HB, Schmechel S, Bitterman PB, Gourdon G, Swanson MS, et al. Non-ATG-initiated translation directed by microsatellite expansions. Proc Natl Acad Sci U S A 108(1):260-265, 2011.